Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice

Targeting the Notch1 and mTOR pathways in a mouse T-ALL model

(2009) K. Cullion et al.   BLOOD

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

(2009) A. Gutierrez et al.   BLOOD

PI3K/AKT pathway activation in acute myeloid leukaemias is not associated with AKT1 pleckstrin homology domain mutation

(2008) Raoul Tibes et al.   BRITISH JOURNAL OF HAEMATOLOGY

Chronic lymphocytic leukaemia and acute myeloid leukaemia are not associated with AKT1 pleckstrin homology domain (E17K) mutations

(2008) T. Zenz et al.   BRITISH JOURNAL OF HAEMATOLOGY

Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells

(2008) Michael G. Kharas et al.   JOURNAL OF CLINICAL INVESTIGATION

TSC–mTOR maintains quiescence and function of hematopoietic stem cells by repressing mitochondrial biogenesis and reactive oxygen species

(2008) Chong Chen et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML

(2008) S Park et al.   LEUKEMIA

Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells

(2008) S Horn et al.   ONCOGENE